-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 17, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration showed that the CTA101 UCAR-T cell injection product independently developed by Nanjing Beiheng Biotechnology Co.
Acute lymphoblastic leukemia is a type of malignant proliferative tumor originating from precursor B or T lymphoid precursor cells in the bone marrow, blood, and extramedullary
CTA101 is a CTA101 cell injection independently developed by Beiheng Biological with independent intellectual property rights
It is reported that CTA101 adopts the "off-the-shelf" CAR-T cell therapy developed by Beiheng Bio's general CAR-T technology platform.
It is reported that the results of the CTA101 exploratory clinical study (IIT) were published in April 2021 in the form of the original paper of Clinical Cancer Research